Dinutuximab beta injection

Datuximab beta injection, trade name Kaiserb, is indicated for the treatment of high-risk neuroblastoma patients aged 12 months and above, and relapsed or refractory neuroblastoma patients with or without residual lesions. This drug is the first targeted immunotherapy drug approved by the China National Medical Products Administration (NMPA) for the treatment of neuroblastoma.
Datuximab beta injection is used to treat high-risk neuroblastoma patients aged 12 months and above, and relapsed or refractory neuroblastoma patients with or without residual lesions.